مقاومت دارویی سرطانهای سر و گردن
ترجمه نشده

مقاومت دارویی سرطانهای سر و گردن

عنوان فارسی مقاله: RNA های غیر کد کننده در مقاومت دارویی سرطانهای سر و گردن: یک مقاله مروری
عنوان انگلیسی مقاله: Non-coding RNAs in drug resistance of head and neck cancers: A review
مجله/کنفرانس: زیست پزشکی و داروسازی – Biomedicine & Pharmacotherapy
رشته های تحصیلی مرتبط: پزشکی، داروسازی
گرایش های تحصیلی مرتبط: ژنتیک پزشکی، پزشکی مولکولی، داروسازی بالینی
کلمات کلیدی فارسی: سرطان سر و گردن، RNA غیر کد کننده، میکرو RNA، RNA غیر کد کننده طولانی، RNA حلقوی، مقاومت دارویی، مقاومت شیمیایی
کلمات کلیدی انگلیسی: Head and neck cancer، Non-coding RNA، MicroRNA، Long non-coding RNA، Circular RNA، Drug resistance، Chemo resistance
نوع نگارش مقاله: مقاله مروری (Review Article)
نمایه: Scopus – Master Journals List – JCR
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.biopha.2020.110231
دانشگاه: Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical University, Taiyuan, 030001, Shanxi, PR China
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2020
ایمپکت فاکتور: 3.829 در سال 2019
شاخص H_index: 78 در سال 2020
شاخص SJR: 0.931 در سال 2019
شناسه ISSN: 0753-3322
شاخص Quartile (چارک): Q2 در سال 2019
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 13
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E14960
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست انگلیسی مطالب

Abstract


Graphical abstract


۱٫ Background


۲٫ Current known mechanisms of HNC drug resistance


۳٫ MiRNAs in HNC cell drug resistance


۴٫ Long non-coding RNAs in HNC cell drug resistance


۵٫ CircRNAs in HNC cell drug resistance


۶٫ Expression of non-coding RNAs is associated with overall survival in HNC


۷٫ Future perspectives


۸٫ Conclusions


Authors’ contributions


Funding


Consent for publication


Availability of data and materials


Declaration of Competing Interest


References

نمونه متن انگلیسی مقاله

Abstract


Head and neck cancer (HNC), which includes epithelial malignancies of the upper aerodigestive tract (oral cavity, oropharynx, pharynx, hypopharynx, larynx, and thyroid), are slowly but consistently increasing, while the overall survival rate remains unsatisfactory. Because of the multifunctional anatomical intricacies of the head and neck, disease progression and therapy-related side effects often severely affect the patient’s appearance and self-image, as well as their ability to breathe, speak, and swallow. Patients with HNC require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapeutics. Chemotherapy is an important part of the comprehensive treatment of tumors, especially advanced HNC, but drug resistance is the main cause of poor clinical efficacy. The most important determinant of this phenomenon is still largely unknown. Recent studies have shown that non-coding RNAs have a crucial role in HNC drug resistance. In addition, they can serve as biomarkers in the diagnosis, treatment, and prognosis of HNCs. In this review, we summarize the relationship between non-coding RNAs and drug resistance of HNC, and discuss their potential clinical application in overcoming HNC chemoresistance.


Background


Head and neck cancer (HNC) is a major global health problem. More than 890,000 new cases of HNC and approximately 450,000 HNC-related deaths occur every year [1,2]. The majority of cases are HN squamous cell carcinoma (HNSCC) [3], involving the stratified epithelium of the oral cavity, pharynx, and larynx, with an overall 5-year survival rate of only 40%–۵۰% [۳]. Most HNC is closely related to tobacco and alcohol use [1–۳]. Patients with HNC might have symptoms including hoarseness, dysphagia, pain, neck mass, and ulcers, which require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapy [4]. Although the treatment is effective for early and locally advanced disease, the prognosis of recurrent and metastatic disease remains poor [5]. Clinically, more than 65% of patients are diagnosed with advanced disease because of the lack of early diagnosis [6]. However, both radiotherapy and surgery reduce patients’ quality of life at this stage [2]. Radiotherapy usually produces obvious side effects, while surgery can significantly affect the normal physiological structure and function of patients [2,7]. Additionally, targeted therapy for HNC has been incorporated into clinical treatment guidelines, but its clinical response and long-term effect are limited, and high costs are associated with this treatment [8]. In recent years, chemical treatment of advanced HNC has been increasingly recognized [9]. In early phase II clinical trials in patients with advanced HNSCC, significant single-agent response rates were up to 30% [5,10].

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

مقاومت دارویی سرطانهای سر و گردن
نوشته های مرتبط
مقالات جدید
لوگوی رسانه های برخط

logo-samandehi

پیوندها